Diabetic Kidney Disease Market Driven by Increasing Prevalence of Diabetes

The diabetic kidney disease market consists of drugs to treat renal disease caused by diabetes. Diabetic kidney diseases are chronic kidney diseases caused by diabetes that can lead to end-stage renal disease requiring dialysis or a kidney transplant. The most common diabetic kidney disease is diabetic nephropathy, which occurs due to long-term high blood sugar levels damaging small blood vessels in the kidneys. Some key drugs to treat diabetic kidney disease include ACE inhibitors, angiotensin-receptor blockers, diuretics, and sodium-glucose transport protein-2 (SGLT2) inhibitors.

The Global diabetic kidney disease market is estimated to be valued at US$ 4.21 Bn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period between 2024 to 2031.

Key Takeaways

Key players operating in The Diabetic Kidney Disease Market are AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb, GSK, Novo Nordisk, Eli Lilly and Company, Merck & Co., Sanofi, AbbVie, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Lupin, Aurobindo Pharma, Takeda Pharmaceutical Company Limited, Biogen, Vertex Pharmaceuticals Incorporated. With the rising prevalence of diabetes globally, there is increasing demand for drugs to treat its complications such as diabetic kidney disease. Various government and private initiatives are being taken up to spread awareness about diabetes management and prevent its further complications like end-stage renal disease. With effective treatment options available, more patients are opting for disease-modifying therapies which is fueling market growth. Key pharmaceutical companies are also expanding their global footprint especially in developing countries to tap the market potential.

Market Drivers

The increasing prevalence of diabetes is a major driver for the growth of the diabetic kidney disease market. According to latest statistics by the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021 worldwide and the number is expected to rise to 643 million by 2030 and 783 million by 2045. Untreated or poorly managed diabetes leads to damage of small blood vessels in the kidneys over a period of time increasing the risk of diabetic kidney disease. Growing awareness about diabetes self-management and treatment of its complications is also boosting the demand for drugs to treat conditions like diabetic nephropathy.

Impact of geopolitical situation on the growth of Diabetic Kidney Disease Market

The growth of the global diabetic kidney disease market is facing challenges due to the ongoing geopolitical tensions and conflicts across several regions. The increasing economic and trade sanctions between various countries are disrupting the supply chains of pharmaceutical companies. This is affecting the consistent production and distribution of drugs for diabetic kidney disease. Furthermore, the healthcare infrastructure and resources are also getting diverted to deal with issues arising out of the geopolitical conflicts. This is limiting further investments in drug research and development activities for diabetic kidney disease.

To tackle these challenges, pharmaceutical companies will need to realign their manufacturing and distribution networks. They may have to rely less on specific countries or regions for raw material sourcing and production. Establishing alternate regional supply chains will help companies ensure steady supplies even during geopolitical tensions. Collaborating more with local partners in different markets can also boost clinical trial activities and new drug launches. This will enable faster market access post approval. Overall, building operational flexibility and global alliances will be critical for pharmaceutical firms to minimize risks arising from geopolitical issues.

Geographical regions where Diabetic Kidney Disease Market is concentrated in terms of value

The diabetic kidney disease drug market is highly concentrated in terms of value in North America and Europe currently. This is mainly due to the rising prevalence of obesity, diabetes and kidney diseases in countries like the United States, Germany, United Kingdom and France. Since these nations have advanced healthcare facilities and high patient affordability for expensive biologic drugs, pharmaceutical companies have been focusing their commercialization efforts here. The per capita healthcare spending is also significantly higher in North America and major Western European countries compared to other regions globally. This supports higher adoption of new treatment options and medical devices for managing diabetic kidney disease in these markets.

Fastest growing region for the Diabetic Kidney Disease Market

The Asia Pacific region is expected to witness the fastest growth in the global diabetic kidney disease market during the forecast period. This is attributed to factors like rapidly growing aging population, increasing urbanization, changing dietary habits and lifestyle diseases in countries like China, India and Japan. The economic development across Asia Pacific has also enhanced access to healthcare with rising medical insurance coverage and greater affordability of new drugs. Additionally, several international pharmaceutical firms are actively expanding their clinical trial presence and partnerships with local generics players in the Asia Pacific to gain early regulatory approvals. This is boosting the sales volume growth of diabetic kidney disease drugs in this high potential region.